• NatureSynthetic


Our Abpromise guarantee covers the use of ab7876 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications


  • FormLiquid
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

    PBS with 0.1% BSA 0.02% sodium azide pH7.2

General Info

  • Alternative names
    • AM4 7
    • C C chemokine receptor type 5
    • C C CKR 5
    • C-C chemokine receptor type 5
    • C-C CKR-5
    • C-C motif chemokine receptor 5 A159A
    • CC Chemokine Receptor 5
    • CC Chemokine Receptor Type 5
    • CC CKR 5
    • CC-CKR-5
    • CCCKR 5
    • CCCKR5
    • CCR 5
    • CCR-5
    • CCR5
    • CCR5 chemokine (C C motif) receptor 5
    • CCR5_HUMAN
    • CD 195
    • CD195
    • CD195 Antigen
    • Chemokine C C motif receptor 5
    • Chemokine receptor CCR5
    • CHEMR13
    • CKR 5
    • CKR5
    • CMKBR 5
    • CMKBR5
    • FLJ78003
    • HIV 1 Fusion Coreceptor
    • HIV-1 fusion coreceptor
    • HIV1 fusion coreceptor
    • IDDM22
    • MIP-1 alpha receptor
    see all
  • FunctionReceptor for a number of inflammatory CC-chemokines including MIP-1-alpha, MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level. May play a role in the control of granulocytic lineage proliferation or differentiation. Acts as a coreceptor (CD4 being the primary receptor) for HIV-1 R5 isolates.
  • Tissue specificityHighly expressed in spleen, thymus, in the myeloid cell line THP-1, in the promyeloblastic cell line KG-1A and on CD4+ and CD8+ T-cells. Medium levels in peripheral blood leukocytes and in small intestine. Low levels in ovary and lung.
  • Involvement in diseaseGenetic variation in CCR5 is associated with suseptibility to diabetes mellitus insulin-dependent type 22 (IDDM22) [MIM:612522]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
  • Sequence similaritiesBelongs to the G-protein coupled receptor 1 family.
  • Post-translational
    Sulfated on at least 2 of the N-terminal tyrosines. Sulfation contributes to the efficiency of HIV-1 entry and is required for efficient binding of the chemokines, CCL3 and CCL4.
    O-glycosylated, but not N-glycosylated. Ser-6 appears to be the major site. Also sialylated glycans present which contribute to chemokine binding. Thr-16 and Ser-17 may also be glycosylated and, if so, with small moieties such as a T-antigen.
    Palmitoylation in the C-terminal is important for cell surface expression, and to a lesser extent, for HIV entry.
    Phosphorylation on serine residues in the C-terminal is stimulated by binding CC chemokines especially by APO-RANTES.
  • Cellular localizationCell membrane.
  • Information by UniProt

References for CCR5 peptide (ab7876)

ab7876 has not yet been referenced specifically in any publications.

Product Wall

Thank you for contacting Abcam.

These peptides are very short fragments of the CCR5 protein and as such may not contain the gp120 binding site. You may wish to use the whole protein. While this is not currently available at Abcam...

Read More

Happy New Year! Thank you for your enquiry. The predicted MW for ab7876: CCR5 peptide is 1.75 kDa. I hope this helps and if I can assist further, please do not hesitate to contact me.

As far as we are aware, this peptide has not been tested in this application